InMed Pharmaceuticals Announces Board Changes and Compensation Updates
Ticker: INM · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1728328
Sentiment: neutral
Topics: board-changes, executive-compensation, corporate-governance
TL;DR
InMed reshuffled its board and updated exec pay; filing includes financials.
AI Summary
InMed Pharmaceuticals Inc. announced on October 9, 2025, a series of significant corporate actions including the departure of two directors, the election of two new directors, and changes to its executive compensation arrangements. The company also filed financial statements and exhibits as part of this report.
Why It Matters
These changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may carry associated risks.
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — Filer
- October 9, 2025 (date) — Earliest event reported
FAQ
Who are the departing directors of InMed Pharmaceuticals Inc.?
The filing indicates the departure of directors but does not name them in the provided text.
Who are the newly elected directors?
The filing mentions the election of new directors but does not provide their names in the provided text.
What specific changes were made to the compensatory arrangements of certain officers?
The filing notes changes to compensatory arrangements but does not detail them in the provided text.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported is dated October 9, 2025.
What is the Standard Industrial Classification code for InMed Pharmaceuticals Inc.?
The Standard Industrial Classification code for InMed Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 801 words · 3 min read · ~3 pages · Grade level 10.1 · Accepted 2025-10-10 17:40:22
Filing Documents
- ea0260877-8k_inmed.htm (8-K) — 30KB
- ea026087701ex99-1_inmed.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-25-098205.txt ( ) — 214KB
- inm-20251009.xsd (EX-101.SCH) — 3KB
- inm-20251009_lab.xml (EX-101.LAB) — 33KB
- inm-20251009_pre.xml (EX-101.PRE) — 22KB
- ea0260877-8k_inmed_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 9, 2025, the Company issued a press release announcing the appointment of Mr. Neil Klompas as a director. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The information set forth in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press Release filed October 9, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: October 10, 2025 By: /s/ Eric A. Adams Eric A. Adams President and CEO 2